http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2189587-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d241f021f09fcc0c7b67778581bffd64 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2001-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65c88d6c89d641c974059cbd002e3a15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_402f771bf3e2a4a64eebe9daeaf89bdb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d556b6e763723db5065f7ac6e92ae7f |
| publicationDate | 2002-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2189587-C1 |
| titleOfInvention | Method for individual selection of medicinal preparations for a certain patient |
| abstract | FIELD: medicine. SUBSTANCE: innovation deals with individual screening of medicinal preparations, both curative ones and nonmedicinal means for a certain patient at different human diseases (inflammatory, oncological, immunodeficient, infectious, etc. ). The method deals with cultivation of patient's blood components together with tested curative preparations, analysis of blood components' substrates before and after cultivation of blood components. One should determine the concentration ratio of thiolic (-SH) and disulfide (-SS) groups in cellular fraction (thiol-disulfide ratio - TDR) to select an optimal preparation. Cultivation of patient's blood components is carried out for 24-72 h, TDR is determined at 30-120-min-long interval, TDR alteration plot as a time function is made and selection of an optimal preparation by comparing the areas under the plots calculated according to TDR and cultivation time data; moreover, cultivation of patient's blood components is performed simultaneously with several curative preparations, cellular fraction obtained out of citrate blood is cultivated, and in selecting medicinal preparations as curative ones for cultivation of blood components it is necessary to apply a tested preparation by taking into consideration its bioavailability at different ways of its introduction into human body (intramuscularly, intravenously, enterally) and, also, by taking into account patient's sex and weight; at selecting curative nonmedicinal means their dosing is carried out as the follows: for curative means of high power (inductothermie, antitumor radiotherapy) the impact time upon patient's blood sample is chosen to be similarly lower against therapeutic one by those times the volume of blood sample is lower than that of the tissues engaged into irradiation area while performing a procedure upon a human body; for curative means of ultralow power and predominantly of informationally-correcting impact (energy-informational therapy) impact duration upon blood sample is chosen to be the same as the time of impact upon a patient while conducting therapeutic procedure; moreover, at using anti-inflammatory and antitumor medicinal chemopreparations as curative ones along with antitumor therapy and other curative means to destroy viability of infectious agent or tumor cell one should select medicinal preparation or curative impact with the lowest area under the plot of TDR dependence against cultivation time, and in applying medicinal preparations and nonmedicinal curative means of immunomodulating, generally strengthening or informationally-correcting impact one should select medicinal preparation or curative impact with the largest area under the plot of TDR dependence against cultivation time. The method provides higher accuracy in selecting curative means, optimization of their doses and combinations. EFFECT: higher efficiency of individual selection. 6 cl, 4 dwg, 4 ex, 4 tbl |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2480760-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2585478-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2560672-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2485503-C2 |
| priorityDate | 2001-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.